NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $302.24 +4.24 (+1.42%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$301.92 -0.32 (-0.11%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Charles River Laboratories International Stock (NYSE:CRL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRL alerts:Sign Up Key Stats Today's Range$294.60▼$305.2050-Day Range$230.58▼$310.8452-Week Range$146.20▼$333.30Volume679,847 shsAverage Volume1.09 million shsMarket Capitalization$14.43 billionP/E RatioN/ADividend YieldN/APrice Target$300.11Consensus RatingModerate Buy Company Overview Charles River Laboratories International, Inc. is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products. Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications. Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia. The company is headquartered in Wilmington, Massachusetts, and its common stock trades on the New York Stock Exchange under the symbol CRL. James C. Foster has served as the company's chairman and chief executive officer for many years.AI Generated. May Contain Errors. Read More Charles River Laboratories International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCRL MarketRank™: Charles River Laboratories International scored higher than 46% of companies evaluated by MarketBeat, and ranked 610th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingCharles River Laboratories International has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 12 buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Charles River Laboratories International is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.27% Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 11.27% in the coming year, from $11.36 to $12.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is -62.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is -62.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 2.83. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.11% of the float of Charles River Laboratories International has been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.69, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently increased by 29.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.65 News SentimentCharles River Laboratories International has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Charles River Laboratories International this week, compared to 5 articles on an average week.Search Interest14 people have searched for CRL on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat Follows2 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have sold 875,285.61% more of their company's stock than they have bought. Specifically, they have bought $2,974.00 in company stock and sold $26,033,968.00 in company stock.Percentage Held by Insiders1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRL Stock News HeadlinesCharles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference CallOctober 9 at 9:07 AM | finance.yahoo.comZacks Research Issues Optimistic Forecast for CRL EarningsOctober 7, 2026 | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 11 at 1:00 AM | Banyan Hill Publishing (Ad)Charles River and Autolomous Partner to Transform Laboratory Execution SystemsOctober 6, 2026 | marketscreener.comMCharles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo PlatformOctober 6, 2026 | marketscreener.comMCharles River Labs and Autolomous launch Apollo Orchestrate for digital lab executionOctober 6, 2026 | msn.comResearch Analysts Offer Predictions for CRL FY2026 EarningsOctober 6, 2026 | americanbankingnews.comCharles River Laboratories International (NYSE:CRL) Reaches New 52-Week High - Time to Buy?October 5, 2026 | americanbankingnews.comSee More Headlines CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $199.62 at the beginning of the year. Since then, CRL stock has increased by 51.4% and is now trading at $302.24. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) announced its quarterly earnings results on Wednesday, August, 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. Charles River Laboratories International's revenue for the quarter was down 2.7% on a year-over-year basis. Read the conference call transcript. Does Charles River Laboratories International have any subsidiaries? The following companies are subsidiaries of Charles River Laboratories International: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and others. Who are Charles River Laboratories International's major shareholders? Charles River Laboratories International's top institutional investors include Confluence Investment Management LLC (0.17%) and Versant Capital Management Inc. Insiders that own company stock include Birgit Girshick, James C Foster, Victoria L Creamer, Glenn Coleman, Joseph W Laplume, William D Barbo, Richard F Wallman, Michael Gunnar Knell, George Massaro, Shannon M Parisotto and Nancy C Andrews. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Home Depot (HD) and Alphabet (GOOG). Company Calendar Last Earnings8/05/2026Today10/11/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CRL's financial health is in the Green zone, according to TradeSmith. CRL has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees19,700Year Founded1947Price Target and Rating Average Price Target for Charles River Laboratories International$300.11 High Price Target$357.00 Low Price Target$219.00 Potential Upside/Downside-0.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.85) Trailing P/E RatioN/A Forward P/E Ratio26.61 P/E Growth2.83Net Income-$144.34 million Net Margins-5.96% Pretax Margin-4.59% Return on Equity15.75% Return on Assets6.51% Debt Debt-to-Equity Ratio0.92 Current Ratio1.35 Quick Ratio1.04 Sales & Book Value Annual Sales$4.02 billion Price / Sales3.59 Cash Flow$21.98 per share Price / Cash Flow13.75 Book Value$64.39 per share Price / Book4.69Miscellaneous Outstanding Shares47,740,000Free Float47,118,000Market Cap$14.43 billion OptionableOptionable Beta1.40 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSE:CRL) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
